Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

Neuromuscular Disorders Topic Center

The US Food and Drug Administration headquarters sign.
News
08/01/2024
The US FDA approved an indication expansion for the gene therapy Elevidys (delandistrogene moxeparvovec-rokl) to include patients with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are nonambulatory and 4...
The US FDA approved an indication expansion for the gene therapy Elevidys (delandistrogene moxeparvovec-rokl) to include patients with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are nonambulatory and 4...
The US FDA approved an...
08/01/2024
Neurology
FDA Approves Efgartigimod Alfa/Hyaluronidase for CIDP Treatment
News
07/29/2024
VYVGART Hytrulo (efgartigimod alfa/hyaluronidase) was recently approved by the Food and Drug Administration (FDA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 
VYVGART Hytrulo (efgartigimod alfa/hyaluronidase) was recently approved by the Food and Drug Administration (FDA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 
VYVGART Hytrulo (efgartigimod...
07/29/2024
Neurology
Doctors examine brain scans
News
06/24/2024
Scores on a cognitive battery showed a statistically significant difference in patients with Huntington disease and healthy control subjects at baseline in a phase 2 study involving the dalzanemdor, an investigational NMDA receptor positive...
Scores on a cognitive battery showed a statistically significant difference in patients with Huntington disease and healthy control subjects at baseline in a phase 2 study involving the dalzanemdor, an investigational NMDA receptor positive...
Scores on a cognitive battery...
06/24/2024
Neurology
A hall of posters for presentation at a professional conference
Conference Coverage
04/01/2024
Jolynn Tumolo
In patients with progressing Duchenne muscular dystrophy (DMD), golodirsen treatment over 6 years delayed loss of ambulation a median 2.4 years compared with matched controls.
In patients with progressing Duchenne muscular dystrophy (DMD), golodirsen treatment over 6 years delayed loss of ambulation a median 2.4 years compared with matched controls.
In patients with progressing...
04/01/2024
Neurology
A teddy bear against a blue background wearing a mask and stethoscope.
News
02/02/2024
Jolynn Tumolo
Children with Rett syndrome who received Anavex 2-73 (blarcamesine) showed improvement on the Rett Syndrome Behaviour Questionnaire (RSBQ) but failed to meet a trial key endpoint for Clinical Global Impression – Improvement (CGI-I).
Children with Rett syndrome who received Anavex 2-73 (blarcamesine) showed improvement on the Rett Syndrome Behaviour Questionnaire (RSBQ) but failed to meet a trial key endpoint for Clinical Global Impression – Improvement (CGI-I).
Children with Rett syndrome who...
02/02/2024
Neurology
A person completes a puzzle of a profile of a head, with a piece missing from where the brain is located.
News
01/16/2024
Jolynn Tumolo
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and fibromyalgia do not appear to be distinct conditions, according to an analysis of cerebrospinal fluid (CSF) proteomes
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and fibromyalgia do not appear to be distinct conditions, according to an analysis of cerebrospinal fluid (CSF) proteomes
Myalgic...
01/16/2024
Neurology
An illustrated picture shows two cartoon doctors, one holding up a magnifying glass to a cartoon brain.
News
11/21/2023
Jolynn Tumolo
The single-dose gene therapy Elevidys (delandistrogene moxeparvovec-rokl) increased motor function in children ages 4 through 7 years with Duchenne muscular dystrophy compared with placebo.
The single-dose gene therapy Elevidys (delandistrogene moxeparvovec-rokl) increased motor function in children ages 4 through 7 years with Duchenne muscular dystrophy compared with placebo.
The single-dose gene therapy...
11/21/2023
Neurology
Conference Coverage
10/11/2023
Jolynn Tumolo
Structural brain abnormalities are more common in patients with spinal muscular atrophy (SMA) compared with typically developing peer controls.
Structural brain abnormalities are more common in patients with spinal muscular atrophy (SMA) compared with typically developing peer controls.
Structural brain abnormalities...
10/11/2023
Neurology
News
04/18/2023
Jolynn Tumolo
A clinical guideline for the respiratory management of patients with neuromuscular weakness was recently released by the American College of Chest Physicians in the journal CHEST.
A clinical guideline for the respiratory management of patients with neuromuscular weakness was recently released by the American College of Chest Physicians in the journal CHEST.
A clinical guideline for the...
04/18/2023
Neurology
News
02/13/2023
Jolynn Tumolo
Huntington disease appears to affect two distinct cell populations in the striatum differently, according to a study published online in Nature Communications by neuroscientists at the Massachusetts Institute of Technology.
Huntington disease appears to affect two distinct cell populations in the striatum differently, according to a study published online in Nature Communications by neuroscientists at the Massachusetts Institute of Technology.
Huntington disease appears to...
02/13/2023
Neurology

Advertisement

Advertisement